GlassScriptPhysician profile
Mark W Knestrick
NPI 1447576673
$782.58
in general payments reported to CMS, 2019-2025
18 companies · $19.49 in 2025
The $19.49 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2022: $207 · 2023: $327 · 2024: $112 · 2025: $19.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $149.20 | 2019-2023 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $127.21 | 2022-2023 | Calquence |
| Celgene Corporation | $82.10 | 2022-2024 | Opdivo |
| Beigene USA, INC. | $58.08 | 2023-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $56.95 | 2023 | |
| Seagen INC. | $47.69 | 2022-2023 | Padcev, Adcetris |
| Amgen INC. | $39.88 | 2023 | Kyprolis, Lumakras |
| Eisai INC. | $38.71 | 2023 | |
| Incyte Corporation | $27.61 | 2022 | |
| Exelixis INC. | $23.36 | 2022 | |
| Genmab U.S., INC. | $23.11 | 2023 | Epkinly |
| Adaptive Biotechnologies Corporation | $19.49 | 2025 | Clonoseq |
| Array Biopharma INC | $16.31 | 2023 | Lorbrena, Xalkori, Mektovi |
| Genzyme Corporation | $15.85 | 2023 | |
| Pfizer INC. | $14.65 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $14.58 | 2023 | Libtayo |
| Daiichi Sankyo INC. | $14.54 | 2024 | Enhertu |
| Tempus Ai, INC | $13.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Knestrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.